Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed

In Amicus Therapeutics, Inc. (NASDAQ:FOLD), Perceptive owned 15.24 million shares worth $83.21 million heading into the third quarter, during which the stock surged by 35.5%. At the end of the second quarter, a total of 23 of the hedge funds tracked by Insider Monkey were long this stock, including Perceptive, which was the largest shareholder of Amicus Therapeutics, Inc. (NASDAQ:FOLD). Another investor with a significant stake was Jeremy Green’s Redmile Group with a $60.6 million position. Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management, William Leland Edwards’ Palo Alto Investors, and Behzad Aghazadeh’s venBio Select Advisor were also bullish on Amicus Therapeutics at the end of June.

Perceptive also held some 3.77 million shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) at the end of June, the stake being valued at $71.84 million. This was by far the most profitable investment of the fund in the third quarter, as Sarepta’s stock surged by over 220% between July and September. During the second quarter, the number of funds from our database long Sarepta Therapeutics Inc (NASDAQ:SRPT) inched up by one to 20. Aside from Perceptive, which also held the largest stake in Sarepta, Point72 Asset Management reported ownership of $52.4 millions worth of the company’s shares. Moreover, Sabby Capital, venBio Select Advisor, and Hudson Bay Capital Management were also bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT).

Disclosure: none